Brean Capital analyst Jason Wittes said the surprise announcement that MiMedx is close to completing DFU and VLU trials for Epifix ahead of the September FDA hearing to discuss the regulator's guidance on human cells, tissues, and cellular and tissue based products removes a major overhang for the stock. The analyst felt most investors assumed the company was not positioned to immediately address the potential for increased regulatory requirements given their strong stance against up-regulation. Wittes reiterated his Buy rating and $12 price target on MiMedx shares.